These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Discovery and Targeting of a Noncanonical Mechanism of Sarcoma Resistance to ADI-PEG20 Mediated by the Microenvironment. Rogers LC; Kremer JC; Brashears CB; Lin Z; Hu Z; Bastos ACS; Baker A; Fettig N; Zhou D; Shoghi KI; Dehner CA; Chrisinger JSA; Bomalaski JS; Garcia BA; Oyama T; White EP; Van Tine BA Clin Cancer Res; 2023 Aug; 29(16):3189-3202. PubMed ID: 37339179 [TBL] [Abstract][Full Text] [Related]
11. Arginine Depletion Therapy with ADI-PEG20 Limits Tumor Growth in Argininosuccinate Synthase-Deficient Ovarian Cancer, Including Small-Cell Carcinoma of the Ovary, Hypercalcemic Type. Ji JX; Cochrane DR; Tessier-Cloutier B; Chen SY; Ho G; Pathak KV; Alcazar IN; Farnell D; Leung S; Cheng A; Chow C; Colborne S; Negri GL; Kommoss F; Karnezis A; Morin GB; McAlpine JN; Gilks CB; Weissman BE; Trent JM; Hoang L; Pirrotte P; Wang Y; Huntsman DG Clin Cancer Res; 2020 Aug; 26(16):4402-4413. PubMed ID: 32409304 [TBL] [Abstract][Full Text] [Related]
12. Arginine Deprivation With Pegylated Arginine Deiminase in Patients With Argininosuccinate Synthetase 1-Deficient Malignant Pleural Mesothelioma: A Randomized Clinical Trial. Szlosarek PW; Steele JP; Nolan L; Gilligan D; Taylor P; Spicer J; Lind M; Mitra S; Shamash J; Phillips MM; Luong P; Payne S; Hillman P; Ellis S; Szyszko T; Dancey G; Butcher L; Beck S; Avril NE; Thomson J; Johnston A; Tomsa M; Lawrence C; Schmid P; Crook T; Wu BW; Bomalaski JS; Lemoine N; Sheaff MT; Rudd RM; Fennell D; Hackshaw A JAMA Oncol; 2017 Jan; 3(1):58-66. PubMed ID: 27584578 [TBL] [Abstract][Full Text] [Related]
13. Intracellular expression of arginine deiminase activates the mitochondrial apoptosis pathway by inhibiting cytosolic ferritin and inducing chromatin autophagy. Feng Q; Bian X; Liu X; Wang Y; Zhou H; Ma X; Quan C; Yao Y; Zheng Z BMC Cancer; 2020 Jul; 20(1):665. PubMed ID: 32677906 [TBL] [Abstract][Full Text] [Related]
14. Selective Intracellular Delivery of Recombinant Arginine Deiminase (ADI) Using pH-Sensitive Cell Penetrating Peptides To Overcome ADI Resistance in Hypoxic Breast Cancer Cells. Yeh TH; Chen YR; Chen SY; Shen WC; Ann DK; Zaro JL; Shen LJ Mol Pharm; 2016 Jan; 13(1):262-71. PubMed ID: 26642391 [TBL] [Abstract][Full Text] [Related]
15. Cisplatin-induced synthetic lethality to arginine-starvation therapy by transcriptional suppression of ASS1 is regulated by DEC1, HIF-1α, and c-Myc transcription network and is independent of ASS1 promoter DNA methylation. Long Y; Tsai WB; Chang JT; Estecio M; Wangpaichitr M; Savaraj N; Feun LG; Chen HH; Kuo MT Oncotarget; 2016 Dec; 7(50):82658-82670. PubMed ID: 27765932 [TBL] [Abstract][Full Text] [Related]
16. Arginine Starvation and Docetaxel Induce c-Myc-Driven hENT1 Surface Expression to Overcome Gemcitabine Resistance in ASS1-Negative Tumors. Prudner BC; Rathore R; Robinson AM; Godec A; Chang SF; Hawkins WG; Hirbe AC; Van Tine BA Clin Cancer Res; 2019 Aug; 25(16):5122-5134. PubMed ID: 31113844 [TBL] [Abstract][Full Text] [Related]
17. Efficacy of arginine depletion by ADI-PEG20 in an intracranial model of GBM. Przystal JM; Hajji N; Khozoie C; Renziehausen A; Zeng Q; Abaitua F; Hajitou A; Suwan K; Want E; Bomalaski J; Szlosarek P; O'Neill K; Crook T; Syed N Cell Death Dis; 2018 Dec; 9(12):1192. PubMed ID: 30546006 [TBL] [Abstract][Full Text] [Related]
18. Arginine deprivation using pegylated arginine deiminase has activity against primary acute myeloid leukemia cells in vivo. Miraki-Moud F; Ghazaly E; Ariza-McNaughton L; Hodby KA; Clear A; Anjos-Afonso F; Liapis K; Grantham M; Sohrabi F; Cavenagh J; Bomalaski JS; Gribben JG; Szlosarek PW; Bonnet D; Taussig DC Blood; 2015 Jun; 125(26):4060-8. PubMed ID: 25896651 [TBL] [Abstract][Full Text] [Related]
19. A role for macrophages under cytokine control in mediating resistance to ADI-PEG20 (pegargiminase) in ASS1-deficient mesothelioma. Phillips MM; Pavlyk I; Allen M; Ghazaly E; Cutts R; Carpentier J; Berry JS; Nattress C; Feng S; Hallden G; Chelala C; Bomalaski J; Steele J; Sheaff M; Balkwill F; Szlosarek PW Pharmacol Rep; 2023 Jun; 75(3):570-584. PubMed ID: 37010783 [TBL] [Abstract][Full Text] [Related]
20. ASS1 as a novel tumor suppressor gene in myxofibrosarcomas: aberrant loss via epigenetic DNA methylation confers aggressive phenotypes, negative prognostic impact, and therapeutic relevance. Huang HY; Wu WR; Wang YH; Wang JW; Fang FM; Tsai JW; Li SH; Hung HC; Yu SC; Lan J; Shiue YL; Hsing CH; Chen LT; Li CF Clin Cancer Res; 2013 Jun; 19(11):2861-72. PubMed ID: 23549872 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]